Trial intelligence / Profile preview

First-line dose-dense R-CHOP14 for diffuse large B-cell lymphoma

2005-005110-20Phase 4Active

Sponsor: GEL/TAMO (Grupo Cooperativo EspaÃ±ol de Linfoma/Transplante AntÃ³logo de MÃ©dula Ã“sea)
Start: Feb 2006
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by GEL/TAMO (Grupo Cooperativo EspaÃ±ol de Linfoma/Transplante AntÃ³logo de MÃ©dula Ã“sea). Primary endpoint: 5-year event-free survival. Started Feb 2006; status: active.

Drugs

rituximabcyclophosphamidedoxorubicinvincristineprednisone

Conditions

diffuse large B-cell lymphoma (DLBCL)

Beyond the preview

Go deeper on 2005-005110-20.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005110-20.